{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:29:31Z","timestamp":1786649371689,"version":"build-2736575974"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Rheumatoid arthritis (RA) is an autoimmune inflammatory condition that adversely affects health-related quality of life (HRQoL) by causing joint damage, pain, functional impairment, and fatigue.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>The aim of this study was to assess the impact of biological disease-modifying antirheumatic drugs (bDMARDs) on fatigue, functional disability, and HRQoL in an Egyptian cohort with RA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This observational analytical prospective cohort study included RA patients who needed to start bDMARDs immediately after the enrolment visit at two Rheumatology and Immunology Units. Clinical, therapeutic, and laboratory data were assessed at baseline and 4 months after administration of bDMARDs, along with the Functional Assessment of Chronic Illness Therapy-Fatigue 13 items, Health Assessment Questionnaire Disability Index (HAQ-DI), and Short Form-12 Health Survey (SF-12) questionnaires.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 85 patients with RA were included (mean age: 41.7 years). Most of the participants were female (87.1%). The most commonly administered bDMARDs were adalimumab (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 26), golimumab (24), and etanercept (15). After bDMARD administration, there was significant improvement in the severity of fatigue (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001, 95% CI: 14.59, 20.29) and median HAQ-DI scores (from 1.68 to 0.68;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001, 95% CI: \u22121.06, \u22120.92). The number of patients with severe to very severe disability decreased significantly from 29 at baseline to 4 after 4 months after administration of bDMARDs (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001). Additionally, the SF-12 domains showed significantly better scores after 4 months compared with baseline.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Administration of bDMARDs is associated with significant improvement in fatigue, functional disability, and health-related quality of life in patients with rheumatoid arthritis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/sjmms.sjmms_747_24","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T13:00:36Z","timestamp":1752670836000},"page":"189-196","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Impact of Biological Therapy on Fatigue, Functional Status, and Health-Related Quality of Life in Rheumatoid Arthritis Patients: Results from Real-Life Practice"],"prefix":"10.4103","volume":"13","author":[{"given":"Samar","family":"Tharwat","sequence":"first","affiliation":[{"name":"Rheumatology and Immunology Unit, Department of Internal Medicine, Faculty of Medicine, Mansoura University, Mansoura, Dakahlia, Egypt"},{"name":"Department of Internal Medicine, Faculty of Medicine, Horus University, New Damietta, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma","family":"Hamdy","sequence":"additional","affiliation":[{"name":"Rheumatology and Immunology Unit, Department of Internal Medicine, Faculty of Medicine, Mansoura University, Mansoura, Dakahlia, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enas S.","family":"Zahran","sequence":"additional","affiliation":[{"name":"Rheumatology and Immunology Unit, Internal Medicine Department, Menoufia University, Shibin El Kom, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abderahman Mohamed","family":"Elsayed","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Mansoura University, Mansoura, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Kamal","family":"Nassar","sequence":"additional","affiliation":[{"name":"Mansoura Nephrology and Dialysis Unit, Department of Internal Medicine, Faculty of Medicine, Mansoura University, Mansoura, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"key":"R1-20260421","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00296-022-05258-2","article-title":"Rheumatoid arthritis study of the Egyptian College of Rheumatology (ECR): Nationwide presentation and worldwide stance","volume":"43","author":"Gheita","year":"2023","journal-title":"Rheumatol Int"},{"key":"R2-20260421","doi-asserted-by":"crossref","first-page":"102400","DOI":"10.1016\/j.jaut.2019.102400","article-title":"The etiology of rheumatoid arthritis","volume":"110","author":"Scherer","year":"2020","journal-title":"J Autoimmun"},{"key":"R3-20260421","doi-asserted-by":"crossref","first-page":"102776","DOI":"10.1016\/j.autrev.2021.102776","article-title":"Rheumatoid arthritis: Extra-articular manifestations and comorbidities","volume":"20","author":"Figus","year":"2021","journal-title":"Autoimmun Rev"},{"key":"R4-20260421","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.apmr.2015.09.022","article-title":"Effects of person-centered physical therapy on fatigue-related variables in persons with rheumatoid arthritis: A randomized controlled trial","volume":"97","author":"Feldthusen","year":"2016","journal-title":"Arch Phys Med Rehabil"},{"key":"R5-20260421","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1136\/annrheumdis-2022-222517","article-title":"Longitudinal trajectories of fatigue in early RA: The role of inflammation, perceived disease impact and early treatment response","volume":"81","author":"Doumen","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R6-20260421","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11926-017-0649-5","article-title":"Fatigue in rheumatoid arthritis","volume":"19","author":"Katz","year":"2017","journal-title":"Curr Rheumatol Rep"},{"key":"R7-20260421","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3904\/kjim.2019.006","article-title":"Association of body composition with disease activity and disability in rheumatoid arthritis","volume":"36","author":"Son","year":"2021","journal-title":"Korean J Intern Med"},{"key":"R8-20260421","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1136\/ard.2009.114652","article-title":"Estimation of a numerical value for joint damage-related physical disability in rheumatoid arthritis clinical trials","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R9-20260421","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1111\/1756-185X.13345","article-title":"Disability and health-related quality of life in Chinese patients with rheumatoid arthritis: A cross-sectional study","volume":"21","author":"Zhou","year":"2018","journal-title":"Int J Rheum Dis"},{"key":"R10-20260421","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.berh.2007.05.004","article-title":"Measuring disability and quality of life in established rheumatoid arthritis","volume":"21","author":"Lillegraven","year":"2007","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"R11-20260421","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jpsychores.2011.01.008","article-title":"An evaluation of a biopsychosocial framework for health-related quality of life and disability in rheumatoid arthritis","volume":"71","author":"Nicassio","year":"2011","journal-title":"J Psychosom Res"},{"key":"R12-20260421","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00296-011-2352-6","article-title":"Factors influencing quality of life (QOL) for Korean patients with rheumatoid arthritis (RA)","volume":"33","author":"Cho","year":"2013","journal-title":"Rheumatol Int"},{"key":"R13-20260421","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1136\/annrheumdis-2019-216656","article-title":"Efficacy of pharmacological treatment in rheumatoid arthritis: A systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"79","author":"Kerschbaumer","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R14-20260421","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 rheumatoid arthritis classification criteria: An American College of Rheumatology\/European League Against rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R15-20260421","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R16-20260421","doi-asserted-by":"crossref","first-page":"339","DOI":"10.32457\/ijmss.2014.042","article-title":"World Medical Association declaration of Helsinki: Ethical principles for medical research involving human subjects. Reviewing the latest version","volume":"1","author":"Cant\u00edn","year":"2014","journal-title":"Int J Med Surg Sci"},{"key":"R17-20260421","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/rheumatology\/ker162","article-title":"Effect of biotherapies on fatigue in rheumatoid arthritis: A systematic review of the literature and meta-analysis","volume":"51","author":"Chauffier","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"R18-20260421","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1136\/ard.2007.084459","article-title":"Validation of the 28-joint disease activity score (DAS28) and European League against rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate","volume":"68","author":"Wells","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R19-20260421","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/cncr.10245","article-title":"Fatigue in cancer patients compared with fatigue in the general United States population","volume":"94","author":"Cella","year":"2002","journal-title":"Cancer"},{"key":"R20-20260421","first-page":"1528","article-title":"Health-related quality of life: Validity, reliability, and responsiveness of SF-36, 15D, EQ\u20135D [corrected] RAQoL, and HAQ in patients with rheumatoid arthritis","volume":"35","author":"Linde","year":"2008","journal-title":"J Rheumatol"},{"key":"R21-20260421","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12955-016-0584-6","article-title":"An empirical evaluation of the SF-12, SF\u20136D, EQ\u20135D and Michigan hand outcome questionnaire in patients with rheumatoid arthritis of the hand","volume":"15","author":"Dritsaki","year":"2017","journal-title":"Health Qual Life Outcomes"},{"key":"R22-20260421","first-page":"S2","article-title":"Treat-to-target: Rationale and strategies","volume":"30","author":"Smolen","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"R23-20260421","first-page":"951","article-title":"Treatment of rheumatoid arthritis by molecular-targeted agents: Efficacy and limitations","volume":"20","author":"Koike","year":"2015","journal-title":"J Orthop Sci"},{"key":"R24-20260421","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/1756-185X.12135","article-title":"Characteristics of patients with rheumatoid arthritis in Qatar: A cross-sectional study","volume":"17","author":"Lutf","year":"2014","journal-title":"Int J Rheum Dis"},{"key":"R25-20260421","doi-asserted-by":"crossref","first-page":"R112","DOI":"10.1186\/ar2001","article-title":"Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: Attrition and long-term evolution of disease activity","volume":"8","author":"Vander Cruyssen","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"R26-20260421","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1136\/annrheumdis-2013-204577","article-title":"Efficacy of biological disease-modifying antirheumatic drugs: A systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"73","author":"Nam","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R27-20260421","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11010-022-04492-3","article-title":"Rheumatoid arthritis: Advances in treatment strategies","volume":"478","author":"Prasad","year":"2023","journal-title":"Mol Cell Biochem"},{"key":"R28-20260421","doi-asserted-by":"crossref","first-page":"680043","DOI":"10.3389\/fphar.2021.680043","article-title":"The therapeutic landscape of rheumatoid arthritis: Current state and future directions","volume":"12","author":"Shams","year":"2021","journal-title":"Front Pharmacol"},{"key":"R29-20260421","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s10067-012-2133-y","article-title":"Perception, consequences, communication, and strategies for handling fatigue in persons with rheumatoid arthritis of working age \u2013 A focus group study","volume":"32","author":"Feldthusen","year":"2013","journal-title":"Clin Rheumatol"},{"key":"R30-20260421","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1136\/annrheumdis-2016-209835","article-title":"The patient perspective on absence of disease activity in rheumatoid arthritis: A survey to identify key domains of patient-perceived remission","volume":"76","author":"van Tuyl","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R31-20260421","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jbspin.2010.05.002","article-title":"Fatigue in patients with rheumatic diseases","volume":"78","author":"Dupond","year":"2011","journal-title":"Joint Bone Spine"},{"key":"R32-20260421","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1093\/rheumatology\/keq043","article-title":"Physical and psychosocial correlates of severe fatigue in rheumatoid arthritis","volume":"49","author":"van Hoogmoed","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"R33-20260421","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/rheumatology\/kew241","article-title":"Most patients who reach disease remission following anti-TNF therapy continue to report fatigue: Results from the British Society for Rheumatology biologics register for rheumatoid arthritis","volume":"55","author":"Druce","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"R34-20260421","doi-asserted-by":"crossref","first-page":"e6771","DOI":"10.7717\/peerj.6771","article-title":"Patient-reported fatigue in patients with rheumatoid arthritis who commence biologic therapy: A longitudinal study","volume":"7","author":"Rinke","year":"2019","journal-title":"PeerJ"},{"key":"R35-20260421","doi-asserted-by":"crossref","first-page":"e001372","DOI":"10.1136\/rmdopen-2020-001372","article-title":"Trajectories of fatigue in actively treated patients with established rheumatoid arthritis starting biologic DMARD therapy","volume":"6","author":"Provan","year":"2020","journal-title":"RMD Open"},{"key":"R36-20260421","doi-asserted-by":"crossref","first-page":"e30123","DOI":"10.1371\/journal.pone.0030123","article-title":"Interleukin-1 inhibition and fatigue in primary Sj\u00f6gren\u2019s syndrome \u2013 A double blind, randomised clinical trial","volume":"7","author":"Norheim","year":"2012","journal-title":"PLoS One"},{"key":"R37-20260421","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1136\/annrheumdis-2018-213378","article-title":"Biologic refractory disease in rheumatoid arthritis: Results from the British Society for Rheumatology biologics register for rheumatoid arthritis","volume":"77","author":"Kearsley-Fleet","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R38-20260421","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/art.20712","article-title":"Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twelve-month randomized, double-blind, placebo-controlled trial","volume":"52","author":"Quinn","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R39-20260421","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3109\/s10165-008-0142-0","article-title":"Improvement of the HAQ score by infliximab treatment in patients with RA: Its association with disease activity and joint destruction","volume":"19","author":"Nagasawa","year":"2009","journal-title":"Mod Rheumatol"},{"key":"R40-20260421","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2169\/internalmedicine.56.8039","article-title":"Clinical characteristics of rheumatoid arthritis patients achieving functional remission with six months of biological DMARDs treatment","volume":"56","author":"Miwa","year":"2017","journal-title":"Intern Med"},{"key":"R41-20260421","first-page":"231","article-title":"Health-related quality of life in early rheumatoid arthritis: Impact of disease and treatment response","volume":"8","author":"Kosinski","year":"2002","journal-title":"Am J Manag Care"},{"key":"R42-20260421","first-page":"1241","article-title":"Quantification of reduced health-related quality of life in patients with rheumatoid arthritis compared to the general population","volume":"34","author":"Uhlig","year":"2007","journal-title":"J Rheumatol"},{"key":"R43-20260421","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11926-015-0501-8","article-title":"Patient reported outcomes in rheumatoid arthritis clinical trials","volume":"17","author":"Orbai","year":"2015","journal-title":"Curr Rheumatol Rep"},{"key":"R44-20260421","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1093\/rheumatology\/kes131","article-title":"Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: Results from the 24-week randomized controlled RADIATE study","volume":"51","author":"Strand","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"R45-20260421","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/art.20159","article-title":"Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate","volume":"50","author":"Maini","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R46-20260421","first-page":"234","article-title":"Improved health-related quality of life with effective disease-modifying antirheumatic drugs: Evidence from randomized controlled trials","volume":"14","author":"Strand","year":"2008","journal-title":"Am J Manag Care"},{"key":"R47-20260421","first-page":"S57","article-title":"Longer term benefits of treating rheumatoid arthritis: Assessment of radiographic damage and physical function in clinical trials","volume":"22","author":"Strand","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"R48-20260421","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1007\/s00296-011-2261-8","article-title":"Baseline HAQ and SF-36 questionnaire scores cannot predict clinical remission, radiographic progression or the need for biological therapy in a three-year prospective study of a Brazilian early rheumatoid arthritis cohort","volume":"32","author":"da Mota","year":"2012","journal-title":"Rheumatol Int"},{"key":"R49-20260421","doi-asserted-by":"crossref","first-page":"151996","DOI":"10.1016\/j.semarthrit.2022.151996","article-title":"Impact of biologics on health-related quality of life in patients with ankylosing spondylitis: A systematic review and meta-analysis of randomized controlled trials","volume":"54","author":"Ho","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"R50-20260421","doi-asserted-by":"crossref","first-page":"e058497","DOI":"10.1136\/bmjopen-2021-058497","article-title":"Effects of bDMARDs on quality of life in patients with psoriatic arthritis: Meta-analysis","volume":"12","author":"Lu","year":"2022","journal-title":"BMJ Open"}],"container-title":["Saudi Journal of Medicine &amp; Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/sjmms.sjmms_747_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:53:16Z","timestamp":1786647196000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/sjmms.sjmms_747_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/sjmms.sjmms_747_24","relation":{},"ISSN":["1658-631X","2321-4856"],"issn-type":[{"value":"1658-631X","type":"print"},{"value":"2321-4856","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"2024-11-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}